Emmetrope Inc. is developing a line of accommodating intraocular lenses (IOLs) called ActaLens, ActaLens-Duo, and ActaLens-SC. The ActaLens models use a restrained hinge mechanism to allow movement of the optic when the eye focuses. Early clinical studies show the ActaLens providing over 0.5mm of movement and an estimated 0.5 diopters of accommodation. The dual optic ActaLens-Duo and shape changing ActaLens-SC are expected to provide even greater accommodation.

1. EMMETROPE
Emmetrope Inc.
• Developing a line of accommodating IOLs
• Broad coverage of restrained lens technology
– Single optic: ActaLensTM,
• Clinical Study Phase, podium presentation at ESCRS 2014
– Dual Optic: ActaLens-Duo
– Shape Change Optic: ActaLens-SC
La Canada, CA
Andrew Phillips, M.D.
President & CEO
3 Versions, same platform:

2. EMMETROPE
ACTIVATED:
RESTRAINT RELEASED1 MONTH CYCLOPLEGIA
YAG
MANUFACTURED RESTRAINED IMPLANTED
MECHANISM

3. EMMETROPE
Total Axial Displacement, 10 Months Post-Implant
UBM (Cyclo-Pilo)
-0.4 -0.2 0 0.2 0.4 0.6 0.8
MM
CrystaLensActaLens
CrystaLens® -.07 + .07 MM
ActaLens® +.48 +.09 MM

4. EMMETROPE
ActaLens Movement
Pentcam HR Total Movement, 1 year
-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6
MM
ActaLensCrystaLens
ActaLens 0.37 + .10
CrystaLens 0.05 + .06

5. EMMETROPE
UBM of ActaLens at 10 Months
Cyclopentalate 1% Pilocarpine 2%
Total axial movement 0.52 MM
REICHERT UBM 35MhZ
16
°
Patient AV, male, 68 y/o, UCVA 20/20-2
31
°

6. EMMETROPE
Estimated Accommodative Effect of Actalens: ~ .5D
axial shift alone may not be sufficient
as lens flexes from observed 10 to 24 degrees
10 degrees
(Cyclopentalate)
24 degrees
(Pilocarpine)

7. EMMETROPE
ActaLens-SC ( Shape-Change)
• Same platform and hinge design as fixed optic version
– Again, .4 MM movement and 10 to 15 degrees flexion
expected
• 2 layer lens. Base layer firmer silicone. Top layer of
softer silicone deforms over base layer as haptics flex.

8. EMMETROPE
ActaLens vs ActaLens-SC
Change in optical power for flexion of haptics from
10 to 24 degrees
Fixed-optic design: ~ .5D Dual-layer shape change: 4D +

9. EMMETROPE
Finite Element Analysis
ActaLens-SC

10. EMMETROPE
Summary
• ActaLens
– UBM, Pentacam, and Lenstar proven movement
– Novel, capsule-independent mechanism
• Actalens-Duo: Dual optic design
– Increases accommodative effect
• Actalens-SC
– Using same clinically tested platform from first
generation Actalens, > 5 D total pharmacological
accommodation expected, lens power
independent.
– Objectively measurable accommodation greater
than 2 D will be crucial to success.

11. EMMETROPE
Evaluation of Movement at 20
Months
• Independent analysis
– VIROS, N. Hirnshall MD, PhD, Findl, O, MD
• Lenstar PCI measurement of cyclo/pilo
axial shift at 20 months confirms
movement:
• .46 MM + .13 total movement of ActaLens
• no axial shift in control group

12. EMMETROPE
Emmetrope Inc.
• Developing a line of accommodating IOLs
• Broad coverage of restrained lens technology
– Single optic: ActaLensTM,
• Clinical Study Phase, podium presentation at ESCRS 2014
– Dual Optic: ActaLens-Duo
– Shape Change Optic: ActaLens-SC
La Canada, CA
Andrew Phillips, M.D.
President & CEO
3 Versions, same platform: